Asston Pharmaceuticals Limited, a pharmaceutical company based in Navi Mumbai, Maharashtra, has announced significant changes in its key personnel. Both the Chief Financial Officer (CFO) and the Company Secretary and Compliance Officer have resigned from their positions.

CFO Resignation

Deven Manohar Patil has stepped down from his role as Chief Financial Officer of Asston Pharmaceuticals Limited. His resignation was effective October 13, 2025, with his last working day being at the close of business hours on the same date. Mr. Patil cited the pursuit of new career opportunities outside the company as the reason for his departure. The Board of Directors received his resignation letter on October 13, 2025.

Company Secretary Resignation

In addition to the CFO's departure, Mrs. Vandana Mishra, who held the position of Company Secretary and Compliance Officer (membership number A64684), has also resigned. Her resignation was effective immediately, with her last working day also being October 13, 2025, at the close of business hours. Like Mr. Patil, Mrs. Mishra is leaving to pursue new career opportunities outside the company.

Company's Response

Saili Jayaram More, Whole Time Director of Asston Pharmaceuticals, filed regulatory disclosures to inform stakeholders of these changes. In compliance with SEBI regulations, specifically Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company provided the following details for Mrs. Mishra's resignation:

Impact and Next Steps

The simultaneous departure of both the CFO and the Company Secretary and Compliance Officer represents a significant change in Asston Pharmaceuticals' leadership team. These roles are crucial for financial management, regulatory compliance, and maintaining good corporate governance practices.

Asston Pharmaceuticals Limited will likely be in the process of finding suitable replacements to fill these important positions. The company has not yet announced any information regarding successors for either Mr. Patil or Mrs. Mishra.

Investors and stakeholders will be watching closely to see how quickly Asston Pharmaceuticals can fill these key roles and ensure a smooth transition in its financial, compliance, and secretarial functions.

Asston Pharmaceuticals Limited (BSE: 544445) has announced a significant international order, showcasing its growing presence in the global pharmaceutical market. The company has received a purchase order worth USD 279,000 from a pharmaceutical company based in West Africa for the supply of various pharmaceutical products.

Order Details

The key details of the order are as follows:

Strategic Implications

This international order marks a significant milestone for Asston Pharmaceuticals Limited, demonstrating the company's capability to cater to global markets. The company views this order as a testament to its commitment to delivering high-quality manufacturing solutions and expects it to strengthen its position in the pharmaceutical industry.

Execution and Delivery

Asston Pharmaceuticals has committed to executing the order within a 60-day timeframe, highlighting the company's confidence in its production and supply chain capabilities. This swift turnaround time for an international order of this scale underscores the company's operational efficiency.

Corporate Governance

In line with regulatory requirements, Asston Pharmaceuticals has confirmed that the transaction does not involve any related party dealings. The company has clarified that its promoter group has no interest in the West African pharmaceutical company awarding the contract, ensuring transparency in its business operations.

Management Statement

Ashish Narayan Sakalkar, Managing Director of Asston Pharmaceuticals Limited, signed off on the regulatory filing, emphasizing the significance of this order for the company's growth strategy and international market expansion.

This development comes as a positive signal for Asston Pharmaceuticals' shareholders and stakeholders, indicating the company's growing international reach and its ability to secure substantial orders in competitive global markets.